Lung Cancer

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).

Lung Cancer

Lung cancer is a common and very serious form of cancer, with more than 40,000 people diagnosed with the condition each year in the UK. The symptoms of lung cancer do not present in the early stages, but when symptoms do eventually present, they usually include the following:

Lung Cancer Screening Procedure

Pulmonary Transplant (Lung Transplant)

Lung Cancer Diagnosis

Lung Cancer Genetics

Exploring Diversity in Lung Cancer: Impact on Incidence, Prognosis, and Treatment Strategies

Secondary Lung Cancer

Epidemiology of Lung Cancer

Lymph Nodes in Lung Cancer

Immunotherapy: The Future of Lung Cancer Treatment?

Pulmonary Resection in Lung Cancer

Lung Cancer Treatments

See more featured articles »

What are the Survival Rates for Lung Cancer?

Lung Cancer Pathogenesis

Lung Cancer Symptoms

Lung Cancer in Women: Understanding the Increasing Risk

Everything You Need to Know About Giving Up Cigarettes

Carcinogens in Cigarette Smoke

What Causes Lung Cancer in Non-Smokers?

How to Prevent Lung Cancer

Palliative and End-of-Life Care in Lung Cancer

Lung Cancer Questions

Lung Cancer Research

Lung Cancer and Electrolyte Imbalances

Types of Lung Cancer Surgery

Lung Cancer Risk Factors

Lung Cancer Causes

Lung Cancer: Radiotherapy and Chemotherapy

Lung Plethysmography Procedure

Latest Lung Cancer News and Research

Researchers reveal why global gains against chronic diseases are stalling

Researchers analysed mortality data from 185 countries and found that while global non-communicable disease (NCD) deaths before age 80 declined from 2010 to 2019, progress slowed compared to 2001–2010. Gains were mainly from drops in heart disease and stroke, but rising burdens from diabetes, cancers, and neuropsychiatric conditions stalled momentum.

15 Sep 2025

AI rollout in NHS hospitals faces major challenges

Implementing artificial intelligence (AI) into NHS hospitals is far harder than initially anticipated, with complications around governance, contracts, data collection, harmonisation with old IT systems, finding the right AI tools and staff training, finds a major new UK study led by UCL researchers.

10 Sep 2025

Lung tumors rewire immune cells in the bone marrow before they reach cancer sites

Lung tumors don't just evade the immune system. They reshape it at its source. Researchers from the Icahn School of Medicine at Mount Sinai and collaborators report in the September 10 online issue of Nature that tumors rewire immune cells in the bone marrow before they even reach the cancer, suggesting a new target to enhance the durability of current immunotherapy

10 Sep 2025

New AI model can identify treatments that reverse disease states in cells

In a move that could reshape drug discovery, researchers at Harvard Medical School have designed an artificial intelligence model capable of identifying treatments that reverse disease states in cells.

10 Sep 2025

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

10 Sep 2025

Emphysema detected on CT predicts mortality from all causes

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic obstructive pulmonary disease (COPD), and cardiovascular disease within a 25-year follow-up period in a new study published today in Radiology, a journal of the Radiological Society of North America.

10 Sep 2025

Combination immunotherapy prior to surgery shows encouraging results in mesothelioma

Results from an early phase clinical trial presented this week at the World Conference on Lung Cancer Meeting in Barcelona, Spain, and published in the Nature Medicine journal today [Monday, 8th September 2025] show that patients with mesothelioma - a rare cancer of the lining of the lung that may be caused by exposure to asbestos - who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, before surgery had successful surgeries and encouraging early outcomes.

9 Sep 2025

Researchers reveal why no level of air pollution is safe for respiratory health

A review in the Journal of Clinical Investigation shows how particulate matter damages the lungs through oxidative stress, inflammation, and immune disruption. It links air pollution to asthma, COPD, lung cancer, infections, and millions of premature deaths, with no safe exposure threshold.

9 Sep 2025

Planetary health diet links to longer life and lower emissions

Greater adherence to the Planetary Health Diet was linked to lower all-cause, cancer, and respiratory mortality across large US and UK cohorts, supported by a meta-analysis of 37 studies. Diets higher in PHD foods also had smaller greenhouse gas footprints, reinforcing health and environmental benefits.

9 Sep 2025

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.

9 Sep 2025

LuCE study identifies key communication barriers between lung cancer patients and caregivers

A large-scale survey conducted by Lung Cancer Europe (LuCE) has identified critical communication barriers that affect information access, understanding, and shared decision-making among lung cancer patients and caregivers across Europe.

9 Sep 2025

Study highlights potential value of low-dose CT screening for lung cancer among Asian women

Results from the Female Asian Nonsmoker Screening Study (FANSS) highlight the potential value of low-dose CT (LDCT) screening for lung cancer among a growing but underserved population: Asian women with no history of smoking.

9 Sep 2025

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).

9 Sep 2025

Mushrooms deliver nutrition medicine and sustainability solutions in one package

This Food Science & Nutrition review highlights mushrooms as nutrient-rich functional foods packed with bioactive compounds that support human health. It explores their therapeutic, industrial, and environmental applications, from disease prevention and drug discovery to bioremediation and bioenergy.

8 Sep 2025

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.

8 Sep 2025

New technology could make MRI scanners cost-effective and more accessible

Revolutionary new technology could make MRI scanners cost effective, more widely available to local communities and help save lives, thanks to a pioneering collaboration between the University of Sheffield and GE HealthCare.

8 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025